Compare · STXS vs TMDX
STXS vs TMDX
Side-by-side comparison of Stereotaxis Inc. (STXS) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both STXS and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.50B, about 19.8x STXS ($126.3M).
- Over the past year, STXS is down 49.9% and TMDX is down 31.3% - TMDX leads by 18.6 points.
- STXS has been more active in the news (7 items in the past 4 weeks vs 5 for TMDX).
- TMDX has more recent analyst coverage (18 ratings vs 6 for STXS).
- Company
- Stereotaxis Inc.
- TransMedics Group Inc.
- Price
- $1.29-8.48%
- $72.31+1.53%
- Market cap
- $126.3M
- $2.50B
- 1M return
- -20.80%
- -6.89%
- 1Y return
- -49.90%
- -31.29%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- AMEX
- NASDAQ
- IPO
- 2019
- News (4w)
- 7
- 5
- Recent ratings
- 6
- 18
Stereotaxis Inc.
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest STXS
- Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026
- University of Szeged Pioneers First Robotic Cardiology Program in Hungary
- Stereotaxis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form S-3 filed by Stereotaxis Inc.
- SEC Form S-3 filed by Stereotaxis Inc.
- Stereotaxis Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Stereotaxis Completes Acquisition of Robocath
- Director Shamir Nachum was granted 43,103 shares, increasing direct ownership by 32% to 179,327 units (SEC Form 4)
- Director Benfer David was granted 43,103 shares, increasing direct ownership by 8% to 558,975 units (SEC Form 4)
- Director Levin Ross B was granted 43,103 shares, increasing direct ownership by 7% to 621,248 units (SEC Form 4)
Latest TMDX
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)
- President & CEO Hassanein Waleed H was granted 49,669 shares, increasing direct ownership by 41% to 171,093 units (SEC Form 4)
- TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
- Director Gunderson Thomas J. exercised 19,285 shares at a strike of $2.21 and sold $722,377 worth of shares (9,624 units at $75.06), increasing direct ownership by 138% to 16,642 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)